Navigation Links
TorreyPines Therapeutics Licenses Intellectual Property from Johns Hopkins Related to Novel Uses of Glutamate Receptor Antagonists for Prevention, Treatment of Stroke, Heart Attack
Date:5/1/2008

- Research Published in March Issue of Journal of Experimental Medicine - - Findings Underscore Versatility of TorreyPines' AMPA/Kainate Receptor

Antagonists as Possible Antithrombotic Agents -

LA JOLLA, Calif., May 1 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that it has signed an exclusive license agreement with Johns Hopkins University (JHU) for intellectual property related to the novel use of glutamate receptor antagonists, including the company's lead compounds tezampanel and NGX426, for the prevention and treatment of stroke, heart attack and other conditions associated with increased platelet aggregation. Financial terms of the license agreement were not disclosed.

The intellectual property is based on research conducted in the JHU laboratories of Craig Morrell, D.V.M., Ph.D., and Charles Lowenstein, M.D., that demonstrates the importance of glutamate release in promoting platelet activation and thrombosis and which identifies the AMPA receptors on platelets as a new antithrombotic target. Published in the March issue of The Journal of Experimental Medicine, the research shows that platelets treated with an AMPA receptor antagonist are more resistant to agonist-induced aggregation than untreated platelets. The studies also show that mice treated with an AMPA receptor antagonist have a prolonged time to clot formation and blood vessel occlusion compared with control mice.

"This is breakthrough research that further illustrates the importance of glutamate receptors as a new target for a wide range of indications," said Neil Kurtz, M.D., President and Chief Executive Officer of TorreyPines Therapeutics. "Additionally, the findings underscore the versatility and co
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Gamma Secretase Modulators Show Promise in Alzheimers Disease Animal Model Efficacy Studies, According to Research Conducted by TorreyPines Therapeutics
2. TorreyPines Therapeutics to Present at BMO Capital Markets Focus on Healthcare Conference
3. TorreyPines Therapeutics to Present at the JMP Securities Healthcare Focus Conference
4. Transition Therapeutics to Present at 2008 Morgan Stanley Global Healthcare Unplugged Conference
5. Duska Therapeutics Plans 505(b)(2) NDA Filing Route for ATPace(TM)
6. Echo Therapeutics and Cato BioVentures Sign Right of First Offer Agreement for Dermatology Products and Transdermal Drug Delivery Technologies
7. CV Therapeutics to Announce 2008 First Quarter Financial Results on Friday, April 25, 2008
8. Precision Therapeutics Adds 8 Million Covered Lives Under Contract
9. Hyperion Therapeutics Elects Lota Zoth to Board of Directors
10. Antisense therapeutics scientist out to pull more big deals
11. Vista Partners Initiates Coverage on Arana Therapeutics (ASX: AAH; AIM: AAHx)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ... August 03, 2015 , ... ... solutions for drugs, biologics and consumer health products, today welcomed the announcement by ... OPKO’s New Drug Application for a new treatment for chronic kidney disease (CKD) ...
(Date:8/3/2015)... ... 2015 , ... Dental practice in Los Angeles , Sunset Plaza Dental, ... that general health emergencies, such as broken arms or a heart attack, should be ... turn to during a dental emergency. This is important, because dental trauma is extremely ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... of its industry-defining contract lifecycle management solution, as well as announced the date ... increase the speed and ease of contract management tasks as well as enhancements ...
(Date:8/3/2015)... ... August 03, 2015 , ... Results ... Navigant Center for Healthcare Research and Policy Analysis show widespread support for the ... said they agreed or strongly agreed that the controversial law passed in 2010 ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... development of it’s new program “Designing Secure Healthcare Systems” This three-day, highly ... technology leaders from healthcare organizations with access to the tactics, techniques and practices ...
Breaking Medicine News(10 mins):Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3Health News:Novatus Unveils Milestone Software Release 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4
... HealthDay Reporter , MONDAY, Nov. 14 (HealthDay News) -- With ... over the past 40 years, the amount of estrogen entering ... incidence of prostate cancer around the world, Canadian researchers speculate. ... the widespread use of the pill might raise environmental levels ...
... noninvasive diagnostic test for coronary artery disease is associated ... and higher health-care spending. That,s according to an observational ... Stanford University School of Medicine. In the study, ... of the Journal of the American Medical Association, ...
... patients with epilepsy who were treated for extended periods ... increased risk for developing atherosclerosis, a common disorder known ... now available in Epilepsia , the journal of ... is significantly associated with the duration of AED monotherapy. ...
... from the Walter and Eliza Hall Institute of Medical ... his research into the control of cell death. , ... Victorian Government to a scientist whose discovery has significantly ... is an important biological process that removes unwanted or ...
... a vibrating platform, is sometimes advertised as being able ... postmenopausal women has shown that it has no such ... of Whole-Body Vibration (WBV) on Bone Density and Structure ... in the November 15, 2011 issue of the ...
... survive breast cancer show significant neurological impairment, and outcomes ... chemotherapy, according to a report in the November issue ... the JAMA/Archives journals. Breast cancer (BC) is one ... worldwide estimated incidence of 39 per 100,000 individuals annually. ...
Cached Medicine News:Health News:Could Women's Use of 'the Pill' Raise Men's Prostate Cancer Risk? 2Health News:Could Women's Use of 'the Pill' Raise Men's Prostate Cancer Risk? 3Health News:New test for coronary artery disease linked to higher rates of cardiac procedures and greater costs 2Health News:New test for coronary artery disease linked to higher rates of cardiac procedures and greater costs 3Health News:New test for coronary artery disease linked to higher rates of cardiac procedures and greater costs 4Health News:Vascular risk linked to long-term antiepileptic drug therapy 2Health News:Cell death research wins professor Andreas Strasser 2011 Victoria Prize 2Health News:Popular whole-body-vibration exercise: not an effective therapy for the prevention of bone loss 2Health News:Neurological and executive function impairment associated with breast cancer 2
(Date:8/3/2015)... , Aug. 3, 2015 VWR ... products, services and solutions, announces the redesign of its global ... When visiting the new site, guests will ... bold colors and vivid images.  Each country site now includes: ... A to Z product menu; and , the ability ...
(Date:8/3/2015)... -- Biosensors International Group, Ltd. ("Biosensors" or the ... a developer, manufacturer and marketer of innovative medical ... fiscal quarter ended 30 June 2015 ("Q1 FY16"). ... , Biosensors continued to make ... by lower operating expenses and operational improvement. Operating ...
(Date:8/3/2015)... 3, 2015 /OFF HOLD ... LLC, PIV757417 The following release: "Biotech Advancements Coupled ... Products & Treatments for Critical-Care Patients With Severe ... 3 Aug 2015 12:30 GMT Cooperative ... surgical research and top-tier universities for identifying biotech ...
Breaking Medicine Technology:VWR's New Website Redesign Provides Improved Functionality for Customers 2Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 2Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 3Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 4Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 5Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 6/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 2/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 3/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 4/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 5/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 6
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: